BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistent with these reports, we and others have previously shown that the BH3 mimetics, ABT-737 and ABT-263 which target BCL2 family members, can significantly enhance TKI-induced cell death in primary CML cells [6-9].